Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesColorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Hildebrand JS et al. – Our results suggest a strong inverse association of long-term use of E-only with colorectal cancer risk, underscoring the importance of collecting data on duration of hormone use in epidemiologic studies of postmenopausal hormones and risk of disease.
Methods- Using data from Cancer Prevention Study II Nutrition Cohort, examined associations of colorectal cancer risk with E-only and E + P, including analyses by recency and duration of hormone use
- During 13.2 years of follow-up, 776 cases of invasive colorectal cancer occurred among 67,412 postmenopausal women participants
- Cox proportional hazards models used to estimate multivariate-adjusted relative risks (RR) and 95% confidence intervals (95% CI) of colorectal cancer for current and former hormone users according to hormone type and duration of use
- Relative to women who never used postmenopausal hormones, current, but not former, use of E-only was associated with a reduced risk of colorectal cancer
- Among current E-only users, duration of use inversely and linearly associated with risk
- Use of E-only for < 5 years not associated with reduced risk, whereas use for ≥ 20 years associated with 45% reduction in risk
- No statistically significant associations between E + P and colorectal cancer risk
Janet S. Hildebrand, 10/29/09
| Approximately 40% of U.S. women aged 50-74 are estimated to have been using menopausal hormones as of the mid 1990s; use declined dramatically following the 2002 publication of results from the Women’s Health Initiative randomized trials. (JAMA 2004;291:47-53) Given that hormone use is now known to increase risk of breast cancer and cardiovascular disease, our finding of a potential benefit for colorectal cancer is unlikely to influence current clinical practice. Unlike the long-term estrogen-only users in our cohort, who began hormone use when it was routinely being prescribed for prevention of chronic diseases in addition to the relief of menopausal symptoms, women today are more likely to use hormones only for immediate relief of vasomotor symptoms and only for the shortest possible duration. Since the reduced risk of colorectal cancer observed in our cohort did not emerge until after 5 or more years of estrogen use, our findings are not likely to be relevant to the colorectal cancer risk profiles of most women initiating hormone use now. Our results, however, do indicate that women who are continuing long-term use of estrogen replacement therapy are at somewhat lower risk of developing colorectal cancer. |
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of HIF-1alpha and VEGF in colorectal cancer: Association with clinical outcomes and prognostic implications
BMC Cancer, 12/16/09
Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: A prospective observational cohort study
Critical Reviews in Oncology/Hematology, 12/16/09
Role of Notch signaling in colorectal cancer
Carcinogenesis, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor